Does Wegovy Make You Lose Your Appetite — and How Strong Is the Effect?

How does Wegovy actually reduce appetite in the brain and stomach?

Semaglutide is a GLP-1 receptor agonist, meaning it mimics a gut hormone your body already produces after eating. GLP-1 has two main jobs relevant here: it slows gastric emptying (food physically sits in the stomach longer) and it acts on receptors in the hypothalamus, the part of the brain that regulates hunger and satiety. The combined effect is that signals of fullness arrive earlier and persist longer than they normally would.

What this means in practice is that many people on Wegovy describe eating a normal portion and feeling satisfied far sooner, or simply not feeling the pull toward food between meals. Some describe it less as suppressed hunger and more as a kind of quiet indifference to eating, food thoughts that used to dominate the day just… recede. If you want a fuller explanation of how Wegovy curbs appetite and what the research says about the strength of that effect, we've covered it in detail separately. The NHS explains this mechanism clearly on its semaglutide medicines page, which is worth reading alongside any information from your prescriber.

The effect is not simply about willpower being boosted. The biology is doing something substantive. That distinction matters, because it changes how you should approach eating while on treatment, rather than relying on hunger to tell you when and how much to eat, you may need to eat more deliberately and focus on what you're eating rather than how much.

Is this appetite change what causes the weight loss, or is there more to it?

Appetite suppression is the primary driver, but it's not the whole picture. There is evidence that semaglutide also affects food preferences, reducing the reward response to high-calorie or highly palatable foods. Some people notice they stop craving things they previously found hard to resist. That shift in food reward is a separate mechanism from fullness signalling, and researchers are still working to understand exactly how significant it is.

Practically, the weight loss that follows comes from a sustained calorie reduction that most people find far easier to maintain than deliberate dieting. In the STEP 1 trial, published in the New England Journal of Medicine, adults with obesity on 2.4mg semaglutide achieved an average body-weight reduction of around 15% over 68 weeks alongside lifestyle changes. The appetite reduction is the mechanism; the weight loss is the downstream result. If you want a closer look at what the evidence shows about whether semaglutide produces weight loss or primarily suppresses appetite, we've covered that in detail separately.

It is also worth knowing that the appetite effect alone does not explain everything. Reduced calorie absorption, changes to energy expenditure, and behavioural shifts around eating all contribute. The medicine creates conditions that make eating less; the individual's food choices then shape what happens next, which is why what you eat on treatment matters alongside how much.

Can appetite suppression become too strong, and what should you do?

This is a question our prescribers hear most weeks, and it is a fair one. For some people, especially after a dose increase, the appetite reduction moves beyond comfortable and into territory where eating feels genuinely difficult, portions that once felt modest now feel impossible, and skipping meals seems easier than forcing anything down.

That is worth taking seriously. The concern is not the reduced calorie intake itself; it is what happens to protein, hydration, and micronutrient intake when someone stops eating properly. Muscle mass can be lost alongside fat if protein intake falls too low, and dehydration becomes a risk if the desire to drink also diminishes. Our page on what to eat on Wegovy covers practical strategies for keeping nutrition adequate even when appetite is minimal.

If eating has become genuinely difficult, tell your prescriber. The dose schedule can be adjusted; staying at a lower dose longer is an option, and is far preferable to under-eating in a way that undermines the rest of your health. Some people also find that the severity of appetite suppression eases after the first few weeks at a new dose, which is consistent with the GI side-effect profile more broadly, as noted in the NHS guidance on semaglutide.

Does the appetite-suppressing effect last, or does it wear off over time?

The honest answer is that it varies. Many people find the effect is most pronounced in the early weeks of each new dose, and that it settles into something less dramatic once the body has adjusted. That does not mean it stops working; for most people there remains a meaningful baseline reduction in hunger at maintenance dose compared to before treatment.

Some people notice the effect fluctuates week to week, or that particular triggers (stress, poor sleep, social eating occasions) temporarily override the suppression. That is not a sign the medicine has stopped working. The appetite changes that come with Wegovy are documented to persist throughout treatment for the majority of people, though the character of the effect shifts.

What tends to happen when people stop treatment is that appetite returns, which is part of why Wegovy is designed as a long-term medicine rather than a short course. Planning for that is part of the clinical conversation. If you are considering what treatment looks like for you, the full overview of Wegovy covers the treatment journey, eligibility and what to expect at each stage. For those weighing up the cost of private treatment, our Wegovy cost guide sets out what affects pricing and what a legitimate private prescription includes. When you are ready to explore whether treatment is right for you, starting a free consultation is the first step, a GPhC-registered prescriber will review your answers and medical history the same day.